Mean ALT and AST activities were significantly lower in C282Y homozygotes than nonhomozygotes. The probability of being a C282Y homozygote increased as the ALT and AST activities decreased. Conclusion: Patients with hyperferritinemia are more likely to be C282Y homozygotes

if they have normal liver transaminase activities. This paradox could explain the low yields of hemochromatosis screening reported by some liver clinics. (HEPATOLOGY 2012;55:1722–1726) One of the most common genetic disorders in Caucasians is hemochromatosis. Buparlisib Liver disease is the most prevalent, serious complication of iron overload resulting from hemochromatosis, and consequential cirrhosis and hepatocellular carcinoma are common causes of death.1 Hemochromatosis is not an inflammatory liver disease. Liver biopsies from patients with hemochromatosis typically show iron overload, with or without liver fibrosis, and an absence of lymphocytes, leucocytes, and eosinophils. Serum alanine aminotransaminase (ALT) and aspartate aminotransaminase (AST) leak into the circulation as a result of necrosis of hepatocytes and are routinely measured as markers of hepatocellular disease. Many patients are referred to liver clinics for evaluation of elevations in serum ferritin. In such patients, it is common to measure serum transaminases. Other pertinent tests include serum transferrin saturation

and HFE genotyping. Hepatitis B surface antigen (HBsAg) and anti-HCV (hepatitis

C virus) are tested in MCE公司 many patients JQ1 supplier with an elevated serum ALT. Most physicians assume that elevations of serum transaminase activities increase the probability that a patient has hemochromatosis because this is the case with many liver diseases. We found that the probability of HFE 282 Cys Tyr (C282Y) homozygosity decreases as the serum transaminase activities increase. ALT, alanine aminotransaminase; AST, aspartate aminotransaminase; C282Y, 282 Cys Tyr; H63D, 63 His Asp; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HEIRS, Hemochromatosis and Iron Overload Screening Study; HFE, High Iron Fe. The study design and overall results of the Hemochromatosis and Iron Overload Screening (HEIRS) Study have been previously reported.2-4 The HEIRS Study was approved by all local investigational review boards. Participants ≥25 years of age who gave informed consent were recruited from five field centers that serve ethnically and socioeconomically diverse populations. All participants had random testing for serum transferrin saturation and serum ferritin levels (without intentional fasting) and genotyping to detect the common C282Y and H63D mutations of the HFE gene. Participants who reported a previous diagnosis of hemochromatosis or iron overload (treated or untreated) were excluded.